You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ):川寧生物擬進行股份制改造 可為其邁入資本市場奠定基礎
格隆匯 05-29 22:15

格隆匯5月29日丨科倫藥業(002422.SZ)公佈,公司於2020529日召開第六屆董事會第二十九次會議,審議通過了《關於控股子公司犁川寧生物技術有限公司股份制改造的議案》。公司控股子公司伊犁川寧生物技術有限公司(“川寧生物”)擬整體變更為股份有限公司

川寧生物當前主要從事醫藥中間體相關的研發、生產和銷售,主要產品為硫氰酸紅黴素、6-氨基青黴烷酸、7-氨基頭孢烷酸、7-氨基脱乙酰氧基頭孢烷酸以及青黴素工業鹽等。

川寧生物高度重視生產相關的創新與環保技術研發,建設有國家環境保護抗生素菌渣無害化處理與資源化利用工程技術中心,其“生物發酵抗生素生產尾氣處理技術集成及應用”榮獲新疆維吾爾自治區2016科技進步一等獎。目前,川寧生物通過多年在行業內的深耕細作,已發展成為具有綜合競爭優勢的細分行業龍頭企業之一。

作為國內領先的抗生素中間體生產商,川寧生物整體變更為股份公司,是為其在合適的時機選擇符合股東利益及戰略規劃的發展路徑奠定基礎,有利於完善川寧生物的公司治理結構,提升規範運作水平;也有助於川寧生物未來拓寬融資渠道,進一步做強做大,促進企業的可持續健康發展。同時,股份制改造可為寧生物在符合有關法律、法規的條件下邁入資本市場奠定基礎,保障川寧生物持續發展。

公司與川寧生物在人員、資產、財務、機構、業務等方面均保持獨立,各自獨立核算,獨立承擔責任和風險。川寧生物此次股份制改造不會影響公司的控制地位,不會對公司財務及經營狀況產生不利影響,也不存在損害公司及全體股東利益的情形。川寧生物為公司合併報表範圍內的控股子公司,未來川寧生物實現可持續健康發展將對公司的經營發展帶來積極有利的影響,符合公司整體的發展目標及長期發展戰略

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account